The United Kingdom Multiple Sclerosis Register Covid-19 Substudy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-14

Study Completion Date

2022-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 and Multiple Sclerosis Disease Modifying Therapies

NCT04863586

Covid19 Multiple Sclerosis

UNKNOWN

Covid-19 Vaccine Immune Response in Multiple Sclerosis

NCT05269888

Multiple Sclerosis

ACTIVE_NOT_RECRUITING

MS Relapses During COVID-19 Pandemic

NCT04858763

Multiple Sclerosis Covid19 Relapsing Remitting Multiple Sclerosis

UNKNOWN

COVID-19 Vaccine Response in Treated MS Patients

NCT05060354

Multiple Sclerosis Healthy

COMPLETED

Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study

NCT05197699

Multiple Sclerosis (MS)

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study objectives

1. To identify the incidence of upper respiratory tract symptoms: fever, cough and breathing difficulties, other symptoms suggestive of COVID-19 infection, respiratory tract infections suggestive of COVID-19, and COVID-19 confirmed by laboratory testing among the UK MS population
2. To establish if some DMDs increase the risk of COVID-19 infection
3. To determine the incidence and effectiveness of self-isolation in the MS population. To examine the impact self-isolation has on mood, fatigue, and other routinely collected patient reported outcome measures from the MS Register.
4. To determine the clinical outcome of respiratory tract infections, including confirmed and suspected cases of COVID-19, in terms of symptoms, time to recovery, hospital admission, requirement for ventilation, and death.
5. To determine the longer-term impact of COVID-19 on MS, using routinely collected MS outcomes in the MS register, including impact on disability, relapses and changes in DMDs as assessed at 3 monthly intervals.
6. To determine where people are obtaining their health information during the COVID-19 outbreak.
7. To establish changes in DMDs prior to and as a result of symptoms related and unrelated to COVID-19

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Confirmed Cases

Diagnosed by health professional / Covid-19 test

Monitored through fortnightly questionnaires

No interventions assigned to this group

Not Covid-19 cases

Through self report no suspicion of COVID-19, tested by fortnightly questionnaire.

non Covid Cases can become COVID cases through self report.

No interventions assigned to this group

Suspected Covid-19 Cases

Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed.

Fortnighly questionnaire

No interventions assigned to this group